Stock NewsYahooFinance FDA Rejects Acadia’s Supplemental New Drug Application For NUPLAZID; Shares Plunge Shares of Acadia Pharmaceuticals plunged more than 15% in early trade on Monday after the biopharmaceutical company received a Complete Response Letter (CRL) … Priti Ramgarhia, April 5, 2021
Stock NewsYahooFinance Acadia Plunges 12% As Depressive Study Misses Goals; Analyst Says Buy Shares in Acadia Pharmaceuticals (ACAD) plunged 12% in Monday’s extended trading, after the company announced disappointing top-line results from its 298 patient Phase … Harriet Lefton, July 21, 2020
Stock NewsYahooFinance Acadia Files Nuplazid Label Expansion; Analyst Sees ‘Significant’ Potential Acadia Pharmaceuticals Inc. (ACAD) has announced that it has filed a supplemental New Drug Application (sNDA) to the U. Harriet Lefton, June 16, 2020
Biotech StocksTop-Rated Analysts Top Analyst Stands Firm for Acadia Pharmaceutical (ACAD) Stock While its Anti-Depression Medication Goes Through Trial After a series of talks with depression key opinion leaders (KOL) about Acadia Pharmaceutical’s (ACAD) Ph2 CLARITY trial, all four experts believe the … Shanna Fuld, December 3, 2018
Analyst InsightsBiotech Stocks J.P. Morgan’s Cory Kasimov Shares Thoughts on ACADIA Pharmaceuticals (ACAD) Following FDA Approval of Nuplazid Formulations J.P. Jason Cohen, June 29, 2018
Analyst InsightsBiotech Stocks Acadia Pharmaceuticals (ACAD): Another Glimpse Into Nuplazid Safety Profile Acadia Pharmaceuticals (NASDAQ:ACAD) is a biopharmaceutical company based in San Diego and focused on the development of therapeutics to treat central nervous system … Jason Cohen, April 10, 2018
Analyst InsightsBiotech StocksMost PopularTop-Rated Analysts ACADIA Pharmaceuticals (ACAD): Top Analyst Does Not See ‘Real Safety Signal’ for Nuplazid Cowen’s Ritu Baral’s conversations with key experts in the field with Nuplazid experience leave her positive; albeit somewhat ‘cautious’ on the impact of ACAD’s controversy. Julie Lamb, April 10, 2018
Biotech Stocks Here’s Why ACADIA Pharmaceuticals Stock Is Plummeting 25% Today ACADIA Pharmaceuticals (NASDAQ:ACAD) just got hit with a bad bullet: a CNN research report questioning lead asset Nuplazid’s risk/reward as a treatment of … Julie Lamb, April 9, 2018
Biotech StocksStock News Here’s Why ACADIA Pharmaceuticals Inc. (ACAD) Shares Are Diving Today Has Wall Street gone a bit overboard punishing ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)? Jason Cohen, February 28, 2018
Bloggers CornerExclusiveHealthcare Billionaire Israel Englander’s Surprising Q3 Moves In Biotech: Teva Pharmaceutical Industries Ltd (ADR) (TEVA), Valeant Pharmaceuticals Intl Inc (VRX), ACADIA Pharmaceuticals Inc. (ACAD) Israel “Izzy” Englander isn’t afraid to go against the market on TEVA, VRX and ACAD. Harriet Lefton, November 16, 2017
